Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 13Salivary Gland Neoplasms 1Prostate Adenocarcinoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

pembrolizumab 4lenvatinib 3Magnetic Resonance Spectroscopy 3Specimen Handling 2Nivolumab 2Epirubicin 2regorafenib 1gallium 68 PSMA-11 1enfortumab vedotin 1anlotinib 1amivantamab 1abemaciclib 1Tablets 1Surveys and Questionnaires 1Standard of Care 1Radiosurgery 1Pemetrexed 1Observation 1Ipilimumab 1Imatinib Mesylate 1Glutamate Carboxypeptidase II 1Cyclophosphamide 1Combined Modality Therapy 1Carboplatin 1CTLA-4 Antigen 1Blood Specimen Collection 1BMS-906024 168Ga-DKFZ-PSMA-11 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Adenoid Cystic × Glutamate Carboxypeptidase II × 1 year × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡